Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 10/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 6/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL5868074 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29351027 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL12445809 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29388553 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3652 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL8214028 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3651 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL16927354 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Flavopyridol SCHEMBL22580715 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL28199338 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217597-A1 | A CDK9 INHIBITOR FOR USE IN THE TREATMENT OF CANCER IN A SUBJECT HAVING AN ASXL1 MUTATION | Sellas Life Sciences Group, Inc. (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-120152967-A | Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119630651-A | Bifunctional compounds containing substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118726268-A | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-108473957-B | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-116546986-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022210644-A1 | DRUG FOR TREATING WIDE RANGE OF VIRAL INFECTIONS, INCLUDING SARS-COV-2 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 2022-10-06 | — | — | WO | disclosed |
| CN-114945382-A | CD19 and CD22 chimeric antigen receptors and uses thereof | 诺华股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-109803684-B | Combination therapy for the treatment of hepatocellular carcinoma | 卫材 R&D 管理有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |